Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

There is still an unmet need in acute migraine treatment, some patients don't respond properly to acute medication.

There are some interindividual differences in clinical characteristics of migraine attacks. These differences may determine the response to acute treatment. Describing the phenotypical differences between patients who are responders and patients non-responders will allow us to offer a personalized treatment.

The aim of the study is to determine which characteristics are associated with a response or a non-response to acute treatment with sumatriptan.

Participants will be asked to register the headache characteristics and accompanying symptoms during 4 spontaneous migraine attacks and its response to treatment with sumatriptan.

Inclusion criteria

• Migraine with or without aura diagnosis according to ICHD-3 criteria
• <8 migraine days per month
• Be able to read, write and understand instructions.
• Have internet access and mail address
• Signing of the informed consent

Exclusion criteria

• Active preventive treatment for migraine
• Active medication with an effect over the central nervous system
• Serious physical or psychiatric condition
• Cardiovascular or hepatic disease
• Pregnant or breastfeeding women
• Any triptan contraindication
• Severe migraine attacks without previous response to triptans or NSAIDs